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Abstract
Background: Delta like 4 (Dll4)/Notch signaling is a key regulator of tumor angiogenesis. Additionally, the role of Dll4
has been studied on tumor stem cells. However, as these cells are implicated in tumor angiogenesis, it is conceivable
that the effect of Dll4 on these cells may be a consequence of its angiogenic function. Our aim was to evaluate the
expression and dissect the functions of Dll4 in the ApcMin/+ model of colorectal cancer.
Methods: We evaluated the protein expression pattern of Dll4 and other Notch members in the ApcMin/+ tumors
relatively to the normal gut and compared endothelial-specific with ubiquitous Dll4 knockout mice on an ApcMin/+
background.
Results: All Notch pathway members were present in the normal small and large intestine and in the adenomas
of the same regions. Dll4, all Notch receptors and Hes1 expression seemed upregulated in the tumors, with some
regional differences. The same members and Hes5, instead of Hes1, presented ectopic expression in the tumor
parenchyma. Dll4 expression was most pronounced in the tumor cells but it was also present in the tumor blood
vessels and in other stromal cells. Ubiquitous and endothelial-specific Dll4 deletion led to an equivalent reduction
of tumor growth because of a similarly marked tumoral angiogenic phenotype promoting non-productive
vasculature and consequently hypoxia and apoptosis. The ubiquitous Dll4 inhibition led to a stronger decrease of
tumor multiplicity than the endothelial-specific deletion by further reducing tumor proliferation and tumor stem
cell density through upregulation of the cyclin-dependent kinase inhibitors 1C and 1B and downregulation of
Myc, Cyclin D1 and D2 independently of β-catenin activation. This phenotype was associated to the observed
increased epithelial differentiation deviated towards the secretory lineages by Atoh1 and Klf4 upregulation only
in the ubiquitous Dll4 mutants.
Conclusions: Dll4 seems to promote ApcMin/+ tumorigenesis through both angiogenic and non-angiogenic
related mechanisms.
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Background
Colorectal cancer (CRC), one of the most frequent ma-
lignancies in the Western world, is commonly associated
with mutations in the tumor suppressor Adenomatous
polyposis coli (APC) gene both in hereditary [1] and in
sporadic CRC [2]. Mutations of this gene constitutively
activate β-catenin target genes causing tumorigenesis
[3]. The ApcMin/+ mouse, which spontaneously develops
multiple intestinal neoplasms (Min) in the small and
large intestine, is considered a good model to study
CRC [4, 5].
Studies revealed that all of the Notch receptors, their
ligands and some of their effectors (Hes1, 5, 6, 7 and
Atoh1) are expressed in the normal intestinal crypts, the
main niche for stem cells. Dll1 and Dll4 interact with
Notch1 and 2 in the normal gut to maintain the homeo-
stasis of intestinal stem cells [6] by repressing the cyclin-
dependent kinase inhibitors Cdkn1b and Cdkn1c [7].
The Notch signaling pathway also promotes the entero-
cyte/colonocyte differentiation [8, 9], while Atoh1 and
Klf4, which are transcriptionally repressed by Hes1,
specify secretory (goblet, enteroendocrine, and Paneth)
cell differentiation [10, 11].
Activation of Notch1 together with Wnt signalling
seems to be essential to trigger CRC initiation by main-
taining the self-renewal of tumor stem cells [12, 13].
These cells share some characteristics with normal stem
cells but have accumulated oncogenic mutations and lost
growth control. They possess the strongest tumor-
initiating potential of all tumor cells and promote tumor
growth and resistance to many current therapies, including
chemo and radiotherapy [14]. Several intestinal stem cell
markers have been investigated, such as the leucine-rich
repeat-containing G-protein-coupled receptor 5 (Lgr5) and
the B cell–specific Moloney murine leukemia virus inser-
tion site 1 (Bmi1) [15–17]. These two markers are also
present in the normal gut in two functionally different in-
testinal stem cell populations; Lgr5 is present in mitotically
active stem cells that are sensitive to irradiation and Wnt
modulation, while Bmi1 is a marker for a reserve popu-
lation of resistant quiescent injury-inducible stem cells
[18]. In CRC both Lgr5 and Bmi1 positive stem cell
populations are associated with cancer initiation and
progression [15, 17, 19] and are regulated by the Notch
pathway [20, 21].
Accumulating evidence has shown that tumor stem
cells promote tumor angiogenesis and that their main-
tenance depends upon functional angiogenesis [22]. It is
currently widely recognized that tumor growth and
maintenance is dependent on the expansion of the indi-
vidual’s vasculature to the center of the tumor [23]. Pre-
vious work showed that the inhibition of Dll4/Notch
represses tumor growth by promoting dysfunctional an
immature tumoral angiogenesis in a variety of xenograft
and autochthonous mouse models [24–27]. In xenograft
models of CRC anti-Dll4 therapy seems to additionally
reduce the frequency of tumor stem cells [28, 29].
Thus, we set out to characterize the expression pattern
of Dll4 and other Notch members in the ApcMin/+ tumors
relatively to the normal intestine and compare endothelial-
specific with ubiquitous Dll4 loss-of-function mutants to
address the role of Dll4 in intestinal tumor development
in the ApcMin/+ model. In particular, we aimed to assess
whether an effect of Dll4 signalling on the ApcMin/+
tumor stem cells was solely a consequence of its action
on tumor angiogenesis or if other, more direct, mecha-
nisms might be involved.
Methods
Experimental animals
All experiments were conducted in accordance with
the Portuguese legislation for the use of animals for
experimental purposes (Decreto-Lei n° 129/92 and
Portaria n° 1005/92, DR n° 245, série I-B, 4930-42) and
with the European Union legislation (Directive n. 86/
609/EEC, from the 24th November 1986). All animal-
involving procedures in this work were approved by
the national regulatory agency (DGAV – Direção Geral
de Alimentação e Veterinária) and the Institutional
Animal Care and Use Committee (CEBEA – Comissão
de Ética e Bem-Estar Animal) (Approval ID: PTDC/
CVT/71604/2006). All sections of this report adhere to
the ARRIVE Guidelines for reporting animal research
[30]. A completed ARRIVE guidelines checklist is in-
cluded in Additional file 1.
Mice were maintained in a conventional facility in a
12-h light/dark cycle, in ventilated cages with corncob as
bedding, and were given access to standard laboratory
diet and water ad libitum. The welfare of the mice was
regularly monitored.
Mutant C57BL/6J-ApcMin/+/J (ApcMin/+) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME).
Two wild type C57BL/6J male mice were used to ana-
lyse Notch pathway expression in the normal intestine
and two ApcMin/+ male mice were used to characterize
their expression in intestinal tumors.
ApcMin/+ mice were crossed with Dll4 conditional
homozygous mice (Dll4lox/lox). The resulting ApcMin/+;
Dll4lox/lox progeny was crossed with VE-cadherin-Cre-
ERT2 mice to produce endothelial-specific inducible
Dll4 loss-of-function (endoDll4-/-) or with Cag-Cre-
ERT2 mice to produce ubiquitous inducible loss-of-
function (ubiqDll4-/-). When these mice reached 6 weeks,
recombinase cre activity was induced by daily i.p. tam-
oxifen administration (50 mg/kg in 10% ethanol plus
90% cremophor), during 5 days as in [31]. Tamoxifen
treated cre-negative mice were used as controls. Twelve
males per group were used in the analysis.
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Macroscopic analysis of the intestine
At 18 weeks of age the animals were sacrificed and the
small and large intestine were excised, flushed and
opened longitudinally. The macroscopic small and large
intestinal tumors of ApcMin/+ Dll4 mutant mice and con-
trols were counted and measured with a calliper under
the dissection microscope in a blinded manner. Tumor
volume was calculated assuming a hemispherical shape
for the small bowel tumors and a spherical shape for
large intestinal tumors. The volumes of all tumors from
each mouse were added to give the overall tumor burden
per animal. Normal WT small and large intestine and
the tumors of these regions from ApcMin/+ Dll4 mutant
mice and controls were collected.
Histopathological analysis
The collected samples were fixed in 10% formalin solu-
tion for 48 h, dehydrated in alcohol, cleared in xylene,
embedded in paraffin, sectioned at 4 μm and stained
with hematoxylin (Fluka AG Buchs SG Switzerland) and
eosin Y (Sigma, St. Louis, MO) for histopathological
analysis. The lesions observed on the H&E sections from
ApcMin/+ mice were classified as hyperplasias, when only
an increase of the number of cells was observed, or as
adenomas with low and high-grade dysplasia based on
the alterations of the shape of the nucleus, the nucleus
to cytoplasm ratio, cell polarity, chromatin pattern, and
changes in gland architecture.
Periodic Acid-Schiff (PAS) staining (Sigma, St. Louis,
MO) was used to mark the intestinal goblet cells. These
cells were counted in the intestine PAS stained sections
using a 400× magnification.
Immunohistochemical analysis
Three series of sequential 4 μm sections of paraffin
embedded-WT normal small and large intestine and
ApcMin/+ intestinal adenomas from two mice each were
used (2 sections per slide).
After dewaxing and rehydration, endogenous peroxidase
activity was quenched (15 min, 1% H2O2) and antigen re-
trieval was performed (20 min at 95 °C in 10 mmol/L so-
dium citrate buffer, pH 6). The primary antibodies to mark
Dll1, Dll4, Notch1-3, Hes1 and 5 (Abcam, Cambridge, UK)
and Jagged1, Jagged2, Dll3 and Notch4 (Santa Cruz
Biothecnology, California, USA) were diluted in PBS con-
taining 2% bovine serum albumin, and incubated overnight
at 4 °C with the tissue sections. These antibodies have been
previously validated [32–34]. The following morning, the
tissue sections were incubated with goat anti-rabbit (Merck
Millipore, Massachusetts, USA) or rabbit anti-goat (Santa
Cruz Biothecnology, California, USA) horseradish peroxid-
ase–labeled secondary antibody and the staining was re-
vealed with ImmPACT DAB Peroxidase Substrate (100 μl,
Vector Laboratories, Burlingame, USA).
The sections were examined under an Olympus Bx51
microscope with the 40×/0.75 objective (UPlanfL). The
images were captured with a Olympus DP21 camera.
A semi-quantitative analysis of the protein expression
in the epithelium was performed by a pathologist in a
blinded manner. Twelve representative fields for each
staining were evaluated according to a scoring criteria
adapted from [35]. Staining intensity was scored as 0
(negative), 1 (weak), 2 (moderate), and 3 (strong). Percent
positivity was converted to scores as 0 (0%), 1 (1–2%), 2
(3–15%), 3 (16–30%), 4 (31–50%), 5 (51–75%) and 6
(75–100%). A final score was obtained by multiplying
the percentage score by the intensity score.
Immunofluorescence analysis
Small and large intestinal tumors were fixed in a 4% (w/v)
paraformaldehyde in PBS solution at 4 °C for 1 h, cryo-
protected in 15% (w/v) sucrose in PBS solution, embed-
ded in 7.5% (w/v) gelatin in PBS solution, snap frozen in
liquid nitrogen and cryosectioned in 10 and 20 μm-thick
sections. The following primary antibodies were used:
anti-PECAM-1, anti-E-cadherin (BD Biosciences, San
Jose, USA), anti-α-SMA, anti-PCNA, anti-Lgr5, anti-
HIF1α, anti-Cyclin D1 (Abcam, Cambridge, UK), anti-
Dll4 (R&D Systems, Minneapolis, USA), anti-lysozyme
(Dako, Glostrup, Denmark), anti-non-phospho (active)
β-catenin (Cell Signaling Technology, Danvers, USA).
Species-specific secondary antibodies conjugated with
Alexa Fluor 488 and 594 (Invitrogen, Carlsbad, CA)
were used to reveal primary antibody binding. Tissue
sections were incubated with primary antibody over-
night at 4 °C and with secondary antibody for 1 h at
room temperature. Nuclei were counterstained with 4′,
6-diamidino-2-phenylindole dihydrochloride hydrate
(DAPI; Molecular Probes, Eugene, OR).
Fluorescent immunostained sections were examined
under a Leica DMRA2 fluorescence microscope with a
Leica HC PL Fluotar 10 and 20×/0.5 NA dry objective,
captured using Photometrics CoolSNAP HQ, (Photo-
metrics, Friedland, Denmark), and processed with Meta-
morph 4.6-5 (Molecular Devices, Sunnyvale, CA, US).
Morphometric analyses were performed using the NIH
ImageJ 1.37v program. After transforming the RGB im-
ages into binary files, the percentage of white pixels per
field was defined as a positive signal.
Under the effect of 2-2-2 tribromoethanol anaesthesia,
biotin-conjugated lectin from Lycopersicon esculentum
(100 μg/100 μl of PBS) or 1% Evans’ Blue solution
(Sigma, St. Luis, MO, US) were administered in the
caudal vein to mark vessel perfusion and extravasation,
respectively. Both solutions were allowed to circulate for
5 min before the vasculature was transcardially perfused
with 4% (w/v) paraformaldehyde in PBS solution for
3 min. Tumor samples were collected and processed as
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described above. Tissue sections were stained and tumor
perfusion was quantified by determining the percentage
of red PECAM-positive structures that were co-localized
with Streptavidin-Alexa 488 (Invitrogen, Carlsbad, CA,
US) signals. Evans’ Blue is red fluorescent and extrava-
sation was visualized in contrast to green fluorescent
vascular structures.
Apoptosis was measured using the TUNEL assay
(Roche, Mannheim, Germany).
Quantitative transcriptional analysis
Intestinal tumors were snap frozen in liquid nitrogen
until RNA extraction (Qiagen RNeasy). Using the Super-
Script® III First-Strand Synthesis SuperMix for qRT-PCR
(Invitrogen, Carlsbad, CA, USA), first-strand cDNA was
synthesized from total RNA. Real-time PCR analysis
was performed using the comparative CT method [36].
Primer pair sequences are listed in Additional file 2:
Table S1. Gene expression was normalized to β-actin
and in the case of genes expressed in the vasculature it
was additionally normalized to Pecam-1.
Statistical analysis
To compare measurements between control and test
groups, the Mann–Whitney-Wilcoxon test was
performed using the Statistical Package for the Social
Sciences v15.0 (Chicago, IL). Results are presented as
relative average ± SEM. P-values <0.05 and <0.01 were
considered significant (*) and highly significant (**),
respectively.
Results
Notch pathway is upregulated in ApcMin/+ small and large
intestine tumors relatively to the normal intestine
Previous RNA-based studies described the expression
pattern of the Notch pathway components in the normal
gut [37, 38]. However, there is still limited information
about its expression in the ApcMin/+ mouse intestinal tu-
mors. The only existing studies in the ApcMin/+ aden-
omas indicated that the expression of Notch receptors
and ligands was similar to that observed in the crypts,
Hes1 was detected uniformly [8] and Jagged1 was over-
expressed in the tumor tissue with concomitant Notch1
and 2 activation [39]. A more complete overview has not
been produced. Therefore we evaluated the protein ex-
pression pattern of the ligands (Dll1, 3 and 4 and
Jagged1 and 2), receptors (Notch1-4) and chosen effec-
tors (Hes1 and 5) in the normal WT gut. We analysed
the presence of these components in the crypts and villi
of the small intestine, in the bottom and top of the
crypts of the large intestine and in the lamina propria of
both regions as summarized in Additional file 3: Table S2.
Then we evaluated the expression pattern of Notch
components in the ApcMin/+ mouse small and large intes-
tinal adenomas and compared it with that of normal WT
gut epithelium.
In the normal small intestinal crypt epithelium our
protein expression analysis revealed that all Notch mem-
bers, except Dll3, were present (Figs. 1a,d and 3a, d).
Most pathway members were expressed at the bottom of
the crypts, where the proliferative and Paneth cells are
located (Figs. 1a, d and 3a, d). Jagged1, however, was
expressed throughout the crypts, but absent in Paneth
cells (Fig. 1a), whereas Notch4 was only present in
goblet cells (Fig. 1d).
In the normal small intestinal villi epithelium, Dll1,
Dll4 (Fig. 1b) and seldom Notch4 (Fig. 1e) were
expressed in differentiated goblet cells. Dll3, Jagged1 and
2 (Fig. 1b), Notch1 and 3 (Fig. 1e) and Hes1 and 5
(Fig. 3b and e) were found in enterocytes. Notch2
seemed absent in this region (Fig. 1e).
In the bottom of the crypts of the normal large intes-
tine, Jagged1 (Fig. 2a) and Hes5 (Fig. 3j) were diffusely
expressed in the epithelium. Jagged2 (Fig. 2a), Notch1-4
(Fig. 2d) and Hes1 (Fig. 3g) were found in scattered cells
within the lower part of the crypts. Dll1, 3 and 4 seemed
mostly absent in the epithelium of this region (Fig. 2a).
In the top of the crypts of the normal large intestine,
Dll1, Dll4 (Fig. 2b) and Notch4 (Fig. 2e) were expressed
in goblet cells. Dll3, Jagged1 (Fig. 2b), Hes5 and Hes1
(Fig. 3h and k) were expressed in colonocytes. Jagged2
(Fig. 2b), Notch1, 2 and 3 (Fig. 2e) seemed absent in the
epithelium of this region.
All of the members were also present in some cells in
the small and large intestinal lamina propria, mainly
Hes5 (Fig. 3e and k) and Dll3 in the large intestine
(Fig. 2a and b).
In the ApcMin/+ intestinal adenomas, the Notch path-
way members were mostly expressed in some stromal
cell populations, such as neutrophils, and in tumor cells,
predominantly at the periphery of the tumor mass
(Figs. 1c, f, 2c, f and 3c, f, i, l).
The expression level of Dll1, Dll3, Jagged1, Jagged2
(Fig. 1a-c and g), Notch3 (Fig. 1d-f and g), and Hes5
(Fig. 3d-f and m) was similar in the small intestine aden-
omas and the normal tissue epithelium. Dll4 (Fig. 1a-c
and g), Notch1, 2 and 4 (Fig. 1d-f and g), and Hes1
(Fig. 3a-c and m) appeared upregulated.
We observed ectopic expression of Dll4 (Fig. 1c),
Notch2 and 4 (Fig. 1f ) and Hes5 (Fig. 3f ) in the small in-
testine tumor epithelium. Dll4 also appeared in other
tumor cells, besides goblet cells (Fig. 1c). Notch2 (Fig. 1f )
and Hes5 (Fig. 3f ) were present in the goblet cells.
Notch4 was not detected in the goblet cells, being
present in other epithelial cell types (Fig. 1f ).
In the epithelium of the large intestine adenomas,
Jagged1 and Jagged2 had a similar expression level
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to the normal tissue (Fig. 2a-c and g). Dll1 and Dll3
seemed less expressed in the tumor epithelium
(Fig. 2a-c and g), and Dll4 (Fig. 2a-c and g), all
Notch receptors (Fig. 2d-g), and Hes1 (Fig. 3g-i and n)
seemed upregulated. We observed ectopic expression of
Dll4 (Fig. 2c), Notch4 (Fig. 2f ), and Hes5 in the
tumor epithelium (Fig. 3l), which was similar to that
described above for the small intestinal adenomas. In
this region Notch1 and Notch3 was also ectopically
expressed, appearing diffusely in the tumor epithelium
(Fig. 2f ).
Endothelial-specific but mainly ubiquitous inhibition of
Dll4 function delays the development of intestinal tumors
in ApcMin/+ mouse
Notch signaling activation promotes intestinal tumorigen-
esis mediated by Apc loss of function [13]. In the present
study, Dll4 and Jagged1 ligands appear to be the Notch
pathway components with greater expression in the small
and large ApcMin/+ adenomas (Figs. 1c and 2c). Previous
authors found that the inhibition of Jagged1-mediated
Notch signaling is sufficient to reduce the size of the
ApcMin/+ intestinal tumors [39]. However, Dll4/Notch
Fig. 1 Notch pathway expression pattern in the small intestine and in ApcMin/+ small intestinal adenomas. a-g Immunohistochemical analysis of
Notch ligands and receptors expression (indicated by a red arrow) in three series of sequential sections of the normal small intestine of C57Bl/6
mice, and in ApcMin/+ small intestinal adenomas (n = 2 per group, and 2 sections per slide). Control staining was performed with the specific species
IgG. Notch ligands (a-c) and receptors (d-f) expression in the small intestinal crypts (a, d), villi (b, e) and adenomas (c, f). Scale bar = 20 μm. Black arrow
indicates a Paneth cell (a). Red arrow points to an enterocyte (b); Yellow arrow indicates a goblet cell (b); Orange arrow in (c) indicates the tumor
epithelium; Green arrow points out a neutrophil (c). LP lamina propria, S stroma. g Graphic bars represent the average staining score ± SEM for each
protein in the normal small intestine (SI) and adenomas of the same region. *P < 0.05; **P < 0.01
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signaling blockade was never evaluated in the ApcMin/+
model of CRC. It was previously shown that Dll4/Notch
signaling is important to maintain the normal gut homeo-
stasis [6] and therefore may also regulate the process of in-
testinal tumorigenesis. Studies using a xenografted model
of CRC suggested that Dll4, besides promoting a dysfunc-
tional vasculature, could have an additional role maintain-
ing the proliferative cancer stem cells [29]. However, this
was never studied in premalignant lesions, the initiating
event of CRC. We found that in the ApcMin/+ small and
large intestine, Dll4 is strongly expressed in the tumor
epithelium, including in the goblet and Paneth cell lineages
(Figs. 1c, 2c, and Additional file 4: Figure S1A-B), and it is
also present in the tumor endothelium (Additional file 4:
Figure S1C-D). In addition, it is present near the Lgr5
positive stem cells in the normal gut and in the intestinal
ApcMin/+ adenomas (Additional file 4: Figure S1E-H).
Therefore, we decided to elucidate if Dll4 inhibition could
be effective in blocking ApcMin/+ tumor initiation and de-
velopment through angiogenic and/or non-angiogenic
mechanisms. To that end, ApcMin/+ mice with endothelial-
specific (endoDll4-/-) and ubiquitous (ubiqDll4-/-) Dll4
Fig. 2 Notch pathway expression pattern in the large intestine and in ApcMin/+ large intestinal adenomas. a-g Immunohistochemical analysis of
Notch ligands and receptors expression (indicated by a red arrow) in three series of sequential sections of the normal large intestine of C57Bl/6
mice, and in ApcMin/+ large intestinal adenomas (n = 2 per group, and 2 sections per slide). Control staining was performed with the specific
species IgG. Notch ligands (a-c) and receptors (d-f) expression in the large intestine in the bottom (a, d) and top (b, e) of the crypts and in
adenomas (c, f). Scale bar = 20 μm. Red arrow points to a colonocyte (b); Yellow arrow indicates a goblet cell (b); Orange arrow in (c) indicates the
tumor epithelium; LP lamina propria, S stroma. g Graphic bars represent the average staining score ± SEM for each protein in the normal large
intestine (LI) and adenomas of the same region. *P < 0.05; **P < 0.01
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loss-of-function were analysed. At 18 weeks of age both
Dll4 mutants had fewer and smaller tumors than the con-
trols (Fig. 4a-e). Endothelial-specific and ubiquitous Dll4
deletion were more effective reducing tumor number than
individual tumor growth, both in the small and large intes-
tine (Fig. 4a-b). Intestinal tumorigenesis, but not the size
of the tumors, was more affected in the ubiqDll4-/- than in
the endoDll4-/- mutants (Fig. 4a-b). Therefore, the overall
intestinal tumor burden of the ubiqDll4-/- mice was re-
duced 6.4-fold, while in the endoDll4-/- mice it was re-
duced 4.7-fold (Fig. 4c).
In the endoDll4-/- tumors, the efficacy of the
endothelial-specific Dll4 deletion was evaluated through
the expression level of the Notch target gene Hey2 that
was found to be decreased by 3.9-fold relatively to the
controls. For the ubiqDll4-/- mutants we measured Dll4
expression, which was reduced 3.4-fold relatively to the
controls (Additional file 5: Figure S2).
Endothelial-specific and ubiquitous Dll4 deletion have
similar negative impact in the tumor vasculature,
promoting hypoxia and apoptosis in the ApcMin/+ tumors
Given the critical role of Dll4 on tumor angiogenesis
[24–27], we analysed the tumor vasculature, hypoxia
and apoptosis in the endothelial and ubiquitous mutants.
The vascular density of the tumors from the small and
large intestine was increased similarly in the endoDll4-/-
and ubiqDll4-/- mice (Fig. 5a-c). The tumor vascular ma-
turity was evaluated as the density of smooth muscle
cells surrounding the wall of the tumor vessels. In the
endoDll4-/- and ubiqDll4-/- mice there was a similar re-
duction of these smooth muscle cells in the blood ves-
sels of both small and large intestinal tumors (Fig. 5a-b
and d). The functionality of the tumoral vasculature was
evaluated by measuring vessel perfusion and extravasa-
tion. In the endoDll4-/- and ubiqDll4-/- mice the tumors
presented a similar reduction of the vascular perfusion
(Fig. 5e-g) and an equivalent increase of the vascular ex-
travasation in both small and large intestine (Fig. 5h-i).
To evaluate tumor hypoxia, tumoral HIF1α density
was measured. Both endoDll4-/- and ubiqDll4-/- tumors
had an equal increase of the hypoxia level in the small
and large intestine (Fig. 6a-c).
The apoptotic index, measured using the TUNEL assay,
was similarly increased in the tumors of the small and large
intestine in endoDll4-/- and ubiqDll4-/- mutants (Fig. 6d-f).
Ubiquitous deletion of Dll4 has a significantly stronger effect
than endothelial-specific Dll4 deletion in the inhibition of
ApcMin/+ tumor proliferation and neoplastic transformation
In addition to its angiogenic effect, Dll4/Notch seems
to regulate the intestinal cancer cells through other
Fig. 3 Hes1 and Hes5 expression pattern in the small and large intestine and in ApcMin/+ intestinal adenomas. a-l Immunohistochemical analysis
of Notch effectors Hes1 and Hes5 expression (indicated by an arrow) in three series of sequential sections of the normal small and large intestine
of C57BL/6 mice, and in ApcMin/+ small and large intestinal adenomas (n = 2 per group, and 2 sections per slide). Hes1 (a-c) and Hes5 (d-f)
expression in the small intestinal crypts (a, d), villi (b, e) and adenomas (c, f). Hes1 (g-i) and Hes5 (j-l) expression in the large intestine in the
bottom (g, j) and top (h, k) of the crypts and in adenomas (i, l). Scale bar = 20 μm. m-n Graphic bars represent the average staining score ± SEM
for each protein in the normal tissue and adenomas of the small intestine (SI) (m) and large intestine (LI) (n). *P < 0.05; **P < 0.01
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mechanisms [28]. Therefore, we analysed the effect of
endothelial-specific versus ubiquitous Dll4 deletion on
tumor proliferation. We observed that the small and
large intestinal tumor cell proliferation was reduced in
the endoDll4-/- and mainly in the ubiqDll4-/- mice
(Fig. 7a-c). The ubiqDll4-/- mice exhibited a statistically
significant stronger reduction of tumor proliferation
than the endoDll4-/- mice both in the small and large
intestine (Fig. 7a-c).
Additionally, we analysed if Dll4 deregulation was
affecting the ApcMin/+ neoplastic transformation. The
samples were histopathologically classified in hyperpla-
sia, adenoma with low-grade dysplasia and adenoma
with high-grade dysplasia (Additional file 6: Figure S3).
No adenocarcinoma lesions were detected. The ApcMin/+
small and large intestinal neoplastic transformation
seemed to be only delayed in the ubiqDll4-/- mice, as
they presented substantially more lesions of hyperplasia
Fig. 4 Endothelial-specific and ubiquitous Dll4 loss-of-function inhibits the ApcMin/+ small and large intestinal tumor development. a-b Graphic
bars represent the average ± SEM tumor number (a) and volume (b) (mm3) in the small and large intestine of induced ApcMin/+ endoDll4-/- and
ApcMin/+ ubiqDll4-/- mice versus their controls (ApcMin/+ endoDll4+/+ and ApcMin/+ ubiqDll4+/+) at 18 weeks of age. c Graphic bars represent the
average ± SEM tumor burden (mm3) in the whole intestine of the animals described above. One experiment with n = 12 per group. *P < 0.05;
**P < 0.01. d-e Photographs of the small and large intestines (tumors indicated by arrows) collected from the endothelial-specific mutants (d)
and from the ubiquitous mutants (e) versus the respective controls
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and less adenomas with high-grade dysplasia compara-
tive to the controls in the large and, mainly, in the
small intestine (Fig. 7d-e). Thus, in the controls and
endoDll4-/- mice the majority of the small and large in-
testinal lesions were adenomas with high-grade dyspla-
sia, while in the ubiqDll4-/- mice most of the lesions
were hyperplasias and adenomas with low-grade dys-
plasia in the small and large intestine, respectively
(Fig. 7d-e).
Ubiquitous deletion of Dll4 has a stronger inhibitory
effect than the endothelial-specific blockade on ApcMin/+
tumor stem cell maintenance independently of β-catenin
activation
Recent studies showed that the mitotically active Lgr5-
positive and the quiescent Bmi1- positive stem cells are
responsible for intestinal tumorigenesis [15–17] and
that this is regulated by Notch signaling [20, 21].
Therefore, given the observed reduction in the ApcMin/+
Fig. 5 Endothelial-specific and ubiquitous Dll4 deregulation affects similarly the ApcMin/+ tumor angiogenesis. a, b, e, f, h, i Immunofluorescence
stainings of 20 μm small (a, e, h) and large (b, f, i) intestinal tumor cryosections from ApcMin/+ endoDll4-/-, ApcMin/+ubiqDll4-/- mice and controls
(CT) at 18 weeks of age. Scale bars = 100 μm. Representative images of staining density for PECAM-1 (in green) and α-SMA (in red) (a, b), for lectin
(in green) and PECAM-1 (in red) (e, f), and for PECAM-1 (in green) and Evans blue (in red) (h, i). The nuclei were counterstained with DAPI (in blue).
c, d, g, j Graphic bars represent the relative (%) ± SEM small (SI) and large (LI) intestinal tumor vascular density (c), maturity (d), perfusion (g) and
extravasation (j) in the animals described above. One experiment with n = 6 per group and 6 fields per animal. *P < 0.05; **P < 0.01
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small and large intestinal tumor number in the Dll4
knock-out mice compared with the controls, we de-
cided to analyse if Dll4 reduction was affecting the
Lgr5+ and/or Bmi1+ stem cell expression in the tu-
mors. Compared with the controls, Lgr5 protein and
gene expression was reduced in the small and large in-
testinal tumors from both mutants, but mostly in
those from ubiqDll4-/- mice (Fig. 7f-j). Additionally, as
previously shown by Pellegrinet et al., we did not ob-
serve differences in the density of Lgr5-positive stem
cells in the adjacent normal intestine of the mutants
[6] (data not shown). In the case of the Bmi1 stem cell
marker, its expression was only reduced in the
ubiqDll4-/- mice, in both small and large intestinal tu-
mors (Fig. 7i-j). The differences between the two types
of Dll4 mutants in the expression of Lgr5 and Bmi1
markers in the small and large intestinal tumors were
statistically significant (Fig. 7f-j).
Previous reports indicated that Notch signaling seems
to maintain the intestinal stem cells by transcriptionally
repressing the cyclin-dependent kinase inhibitors 1B
(Cdkn1b) and 1C (Cdkn1c) [7]. Accordingly, we ob-
served an increase of Cdkn1b and Cdkn1c gene expres-
sion only in the ubiqDll4-/- small and large intestinal
tumors relatively to the controls and to the endoDll4-/-
mice (Fig. 7i-j).
Myc and cyclin D1 and D2 are important regulators of
intestinal stem cells and are implicated in tumor initi-
ation and progression [40–42]. We observed they were
all downregulated only in the ubiqDll4-/- small and large
intestinal tumors, mostly in the first region, relatively to
the controls and to the endoDll4-/- mice (Fig. 7i-m).
Nonetheless a more thorough analysis should be ad-
dressed to confirm our results at the protein level.
Given the central role of the Wnt signaling in ApcMin/+
tumorigenesis (Sansom, 2004), we measured the tumor
Fig. 6 Endothelial-specific and ubiquitous Dll4 deregulation promotes equally hypoxia and apoptosis in ApcMin/+ tumors. a, b, d, e Immunofluorescence
stainings of 20 μm (a, b) and 10 μm (d, e) cryosections of small (a, d) and large (b, e) intestinal tumors collected from ApcMin/+ endoDll4-/-, ApcMin/+
ubiqDll4-/- and control (CT) mice at 18 weeks of age. Scale bars = 100 μm. Representative images of staining density for PECAM-1 (in green) and HIF1α
(in red) (a, b), and for TUNEL (in green) and PECAM-1 (in red) (d, e). The nuclei were counterstained with DAPI (in blue). c, f Graphic bars represent the
relative (%) ± SEM small (SI) and large intestinal (LI) tumor hypoxia (c) and tumor apoptotic index (f) in the mice described above. One experiment with
n= 6 per group and 6 fields per animal. *P< 0.05; **P< 0.01
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density of the Wnt pathway-derived non-phosphorylated
(active) β-catenin to understand if Dll4 ubiquitous and/or
endothelial-specific inhibition was affecting this pathway.
We did not observe statistically significant differences in
either of the mutants (Additional file 7: Figure S4A-B).
Ubiquitous, but not endothelial-specific deletion of Dll4,
promotes epithelial differentiation and secretory lineage
commitment in the ApcMin/+ tumors
It has been reported that Notch signaling is required for
repression of secretory cell differentiation in colon
Fig. 7 Ubiquitous deletion of Dll4 has a greater inhibitory effect in the ApcMin/+ tumorigenesis and neoplastic transformation than the
endothelial-specific deletion. a, b, f, g, k, l Immunofluorescence stainings of small (a, f, k) and large (b, g, l) intestinal tumor cryosections (10 μm)
from ApcMin/+ endoDll4-/- and ubiqDll4-/- mice versus the controls (CT) at 18 weeks of age. Representative images of staining density for PCNA
(in green) and PECAM-1 (in red) (a, b), for Lgr5 (in green) (f, g), and for Cyclin D1 (in green) (k, l). The nuclei were counterstained with DAPI
(in blue). Scale bars = 100 μm. c, h, m Graphic bars represent the small (SI) and large intestinal (LI) tumor proliferation index (c), and the relative
tumor Lgr5 (h) and Cyclin D1 (m) density (%) ± SEM in the animals described above. One experiment with n = 6 per group and 6 fields per animal.
d, e Graphic bars represent the proportion (%) of hyperplasias and adenomas with low and high-grade dysplasia obtained in the histopathological
analysis (H&E) of the macroscopic small (d) and large (e) intestinal lesions from ApcMin/+ endoDll4-/-, ubiqDll4-/- and control (CT) mice at 18 weeks of
age. One experiment with n = 12 per group. i, j RT-PCR analysis of Lgr5, Bmi1, Cdkn1b, Cdkn1c, Myc, Ccnd2 relative expression in the ApcMin/+ endoDll4-/-
and ubiqDll4-/- small (i) and large (j) intestinal tumor samples from mice at 18 weeks of age. One experiment with
n = 3 per group. *P < 0.05; **P < 0.01
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cancer [12]. Blocking this pathway by removal of its
transcription factor RBP-Jk or by treatment with gamma-
secretase inhibitors, causes a complete conversion of
normal and tumoral intestinal proliferative cells into
post-mitotic goblet cells [8, 39]. This raises the possibility
that the observed reduction of tumoral stem cells might
be related to differentiation towards the secretory cell line-
ages. Therefore we evaluated the density of the epithelial
differentiation marker E-cadherin [43] and determined the
density of Paneth cells in the tumors, by measuring the
level of lysozyme (which is produced by these cells)
and the proportion of goblet cells. Paneth cells are nor-
mally present only in the small intestine, but previous
reports showed Paneth cell metaplasia in large intes-
tinal adenomas [44].
Relatively to the controls, we found a moderate increase
of tumor epithelial differentiation in the ubiqDll4-/-, but
not in the endoDll4-/-, small and large intestine (Fig. 8a-c).
Additionally, the density of Paneth cells and mainly the
proportion of goblet cells were increased only in the
ubiqDll4-/- small and large intestinal tumors (Fig. 8d-j).
The differences between the two Dll4 mutants in the
level of epithelial differentiation and specifically in the
density of Paneth and goblet cells were statistically sig-
nificant (Fig. 8a-j).
We also measured the relative transcription in the tu-
mors of Akp3, Muc2, Lyz1 and Neurog3 markers for the
enterocyte, goblet, Paneth and neuroendocrine cell pop-
ulations, respectively, and also of the promoters of
secretory lineage commitment Atoh1 and Klf4 [10, 45].
Compared with the controls, all the lineage markers
evaluated were significantly increased in the ubiqDll4-/-
tumors, mostly Muc2, and Lyz1 in the small intestine
and Muc2, Atoh1 and Klf4 in the large intestine (Fig. 8k-l).
No significant differences were observed in the endoDll4-/-
small and large intestinal tumors relatively to the controls
(Fig. 8k-l). Nevertheless, further analysis should be con-
sidered to verify if there is a correlation between all the
transcriptional data at the protein level.
Discussion
Activation of Notch pathway seems to promote intes-
tinal tumorigenesis induced by Apc loss [13] and Dll4 is
one of the Notch signaling pathway components found
to be upregulated in these tumors [46]. Reports have
shown that Dll4 inhibition delays the tumor growth by
deregulating the tumor angiogenic process [24–27], but
in CRC anti-DLL4 therapy may also reduce the cancer
stem cell frequency [29]. Despite the advances in the un-
derstanding of Dll4/Notch signaling in cancer, most of
the previous reports were focused on role of Dll4 in the
tumor angiogenic process and further studies are still
needed to unveil all the mechanisms by which Dll4 af-
fects the tumor initiation and development in the gut.
Reports have shown that all Notch receptors, ligands
and some of the Notch target genes are expressed in the
normal gut [8, 37, 38]. However, in the ApcMin/+ intes-
tinal tumors their expression has been poorly described.
A study indicated that expression of Notch receptors
and ligands closely follows the expression in the normal
crypts, while Hes1 expression was observed uniformly in
the adenomas [8]. Other report showed that Jagged1 is
overexpressed in the tumor tissue with concomitant
Notch1 and 2 activation [39]. In the present work we
analysed the protein expression pattern of most Notch
pathway members in the ApcMin/+ intestinal tumors
compared with the normal WT gut. Regarding the previ-
ous gene expression analysis of Notch members in the
normal gut [37, 38], we observed some differences in
our analysis. These included the presence of Notch2 in
the bottom of the large intestinal crypts, of Notch3 and
4 in the small and large intestinal epithelium and Hes1
not only in the small intestinal crypts [37], but diffusely
expressed in the small and large intestine.
Our expression analysis in the ApcMin/+ small and
large intestinal adenomas confirmed that the Notch
pathway is present and activated in intestinal adenomas
harbouring Apc mutations [8, 13, 39, 46]. Dll4 and
Jagged1 were more expressed in these tumors than the
other members of this pathway. Comparing the aden-
omas with the normal WT gut we found that Dll1 and
Dll3 lose their expression in the large intestine. We ob-
served a different expression pattern of Dll4, all Notch
receptors (with regional variation) and Hes5 in the
tumor epithelium. The same Notch members and Hes1,
instead of Hes5, seemed upregulated in the adenomas
(Notch3 only in the large intestine). Thus our expression
analysis indicates that in the ApcMin/+ small and large in-
testinal adenomas, Dll4 is the most upregulated ligand
and is present both in the tumor epithelium and
endothelium.
In the normal gut Dll4 acts redundantly with Dll1 me-
diating the Notch signaling regulation of the intestinal
stem cells proliferation and their commitment towards
de secretory cell fate [6]. We found that Dll4 is
expressed near the Lgr5+ stem cells also in the intestinal
tumors, therefore indicating a possible role of this ligand
in the maintenance of also the tumor stem cells. These
stem cells are believed to be responsible for tumor initi-
ation and progression [47, 48] and depend on proper
angiogenesis to function and survive [22]. Therefore we
intended to elucidate if Dll4 also regulates the fate of
tumor stem cells beside its angiogenic effect in a spon-
taneous model of CRC, the ApcMin/+ mouse. To address
this question we compared ubiquitous with endothelial-
specific Dll4 loss-of-function mouse mutants. Our re-
sults highlighted the importance of Dll4 angiogenic and
epithelial effect during intestinal ApcMin/+ tumor
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initiation and development rather than in maintaining
the normal gut homeostasis. Pellegrinet el al. reported
that in the normal gut, Dll4 intestinal epithelial-specific
inhibition alone is not sufficient to promote a phenotype
due to redundant Dll1-mediated Notch signaling [6].
This lack of intestinal effect after Dll4 inhibition can also
be related to the fact that in the normal gut simultan-
eous inhibition of Notch1 and 2 is necessary to result in
complete conversion of the crypt progenitors into post-
mitotic goblet cells [7] and it is not known whether Dll4
can activate both receptors in the gut. Nevertheless, our
results show that Dll4 seems at least partially responsible
Fig. 8 Ubiquitous, but not endothelial-specific, loss of Dll4 promotes intestinal differentiation towards the secretory lineages. a, b, d, e Immunofluorescence
stainings of small (a, d) and large (b, e) intestinal tumor cryosections (10 μm) from ApcMin/+ endoDll4-/- and ubiqDll4-/- mice versus controls (CT) at 18 weeks
of age. Representative images of staining density for E-cadherin (in green) (a, b) and lysozyme (in green) (d, e). Nuclei were counterstained with DAPI
(in blue). Scale bars = 100 μm. c, f Graphic bars represent the tumor relative (%) ± SEM density of E-cadherin (c) and lysozyme (f) in the small (SI) and
large (LI) intestinal tumors from the animals described above. One experiment with n = 6 per group and 6 fields per animal. g, h PAS staining (of goblet
cells) of paraffin-embedded small (g) and large (h) intestinal tumor sections (4 μm) from ApcMin/+ endoDll4-/- and ubiqDll4-/- mice versus controls (CT) at
18 weeks of age. Scale bars = 100 μm. i, j Graphic bars represent the relative proportion (%) ± SEM of goblet cells in the small (i) and large (j) intestinal
tumor epithelium from the animals described above. One experiment with n = 6 per group and 6 fields per animal. k, l RT-PCR analysis of Akp3, Muc2,
Lyz, Neurog3, Atoh1, Klf4 relative expression in the ApcMin/+ endoDll4-/- and ApcMin/+ ubiqDll4-/- small (k) and large (l) intestinal tumor samples.
One experiment with n = 3 per group. *P < 0.05; **P < 0.01
Badenes et al. BMC Cancer  (2017) 17:50 Page 13 of 17
for the known effects of Notch activation during intes-
tinal tumorigenesis, as Dll4 ubiquitous deletion led to a
similar, but less pronounced, epithelial phenotype as the
pan-Notch/gamma-secretase inhibition in the ApcMin/+
tumors [8]. However, as the alterations were moderated
with no macroscopic repercussions (no observed in-
crease of mucus secretion) in the ubiquitous Dll4 mu-
tants’ gut, Dll1 may partially compensate the lack of Dll4
in this setting and/or Dll4 may not activate both Notch1
and 2 receptors. In addition, as we only analysed the
Lgr5 and Bmi1 positive stem cell populations, it is not
certain if this pathway can affect similarly all the stem
cells present in the intestinal tumors.
We found that ubiquitous and endothelial-specific
Dll4 blockade led to a similar phenotype in the small
and large intestine, but a stronger effect on tumor initi-
ation was observed in the small intestine and a greater
impact on tumor growth was seen in the large intestine.
By comparing the ubiquitous mutants with the endo-
thelial-specific knockouts we found that the observed epi-
thelial phenotype is probably caused by the deregulation
of the tumor angiogenesis but also by other important
mechanisms. Both ubiquitous and endothelial-specific
mutants had an equivalent angiogenic phenotype, with
equally increased hypoxia and apoptosis leading to similar
reduction of the tumor volume. Therefore, Dll4 deletion
inhibited the intestinal tumor growth by inducing a dys-
functional and immature angiogenesis that led to hypoxia
and therefore apoptosis as previously reported in other
tumor models [24, 26, 27, 49].
The multiplicity of tumors was also reduced in the mu-
tants relatively to their controls and this effect was more
pronounced in the ubiquitous than in the endothelial-
specific mutants, associated to a stronger reduction of
tumor cell proliferation and tumor stem cell density in the
first mutants. The stronger inhibitory effect on tumor cell
proliferation through Dll4 ubiquitous deletion may have
therefore prevented the accumulation of more mutations
that lead to tumor initiation, promote the transition of
microadenomas to macroadenomas and favor the
neoplastic transformation. Therefore in the intestinal
adenomas, Dll4 seems to promote proliferation and
maintain the stem cells through angiogenic, but also
non-angiogenic related mechanisms. Indeed we ob-
served decreased expression of Myc, cyclin D1 and D2,
independently of β-catenin activation, only in the
ubiqDll4-/- tumors.
The Wnt signaling has been considered a crucial
player in the initiation of CRC associated to inactive mu-
tations in the APC gene [3]. Nuclear accumulation of β-
catenin promotes neoplastic conversion by triggering the
cell cycle-regulators Cyclin D1 and D2 and Myc and,
consequently, uncontrolled cell proliferation contribut-
ing to tumor progression [40, 50, 51]. Notch signaling
seems to cooperate with Wnt signaling to trigger intes-
tinal tumorigenesis, as activation of Notch in Apc mu-
tant mice led to a significant increase in the number of
adenomas developed [13]. Additionally, a previous study
indicated that Jagged1 was the link between Wnt and
Notch pathways in the ApcMin/+ tumorigenesis, where β-
catenin seems to transcriptionally activate Jagged1 [39].
However, it has been shown that the Mastermind-like 1
co-activator of Notch pathway can bind to the pro-
moters of Cyclin D1 and Myc in colon cancer cell lines
[52] and these molecules are activated directly by
Notch1 in other types of cancer [53–57] and possibly by
Cyclin D1 in CRC [58]. It has been also demonstrated
that Cyclin D2 and Myc are also induced by Notch1 to
promote stem cell renewal in another setting [59]. Addi-
tionally, the overexpression of Dll4 in a leukemia cell
line led to increased protein expression of Myc [60].
Therefore, during ApcMin/+ tumorigenesis Dll4/Notch
signaling may directly upregulate the expression of Cyc-
lin D1 and D2 and Myc. We observed that Dll4 deletion
reduced tumorigenesis without affecting β-catenin nu-
clear accumulation and thus Wnt activation. Therefore,
Dll4/Notch activation may promote intestinal tumori-
genesis by angiogenic and non-angiogenic mediated
mechanisms in a β-catenin independent manner. The
non-angiogenic related regulation may include a syner-
gistic effect of Dll4/Notch with Wnt signaling to pro-
mote tumorigenesis by increasing the transcription of
important Wnt target genes.
In addition, Dll4 ubiquitous inhibition upregulated the
zinc finger-containing transcription factor KLF4 in the
ApcMin/+ tumors. KLF4 is a cell proliferation inhibitor
and can act as a tumor suppressor, being normally
downregulated in ApcMin/+ tumors and in early stages of
human CRC [61]. The loss of one of its alleles increases
ApcMin/+ tumorigenesis, possibly by derepressing β-
catenin mediated gene expression [62]. A previous work
indicated that Notch signaling supresses KLF4 expres-
sion in intestinal tumors and colorectal cancer cells [62].
Our results indicate that Dll4 seems to be the ligand re-
sponsible for this Notch-mediated phenotype. Therefore,
Dll4/Notch may promote carcinogenesis by upregulating
the transcription of Wnt target genes through KLF4
downregulation in the Apc mutated tumors. Previous
work indicated that Hes1 downregulation by Notch in-
hibition derepresses Atoh1, which seems to induce KLF4
upregulation to promote goblet cell differentiation in a
redundant manner [11, 63]. However, it seems that Hes1
may act both upstream and downstream of Atoh1 to
negatively regulate KLF4 [11]. We found that in the ubi-
quitous, but not in the endothelial-specific, Dll4 knock-
outs, the reduction of Lgr5 and Bmi1 positive tumor
stem cell density was accompanied with increased tumor
epithelium differentiation with a moderate deviation
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towards the secretory lineages, probably due to the ob-
served Atoh1 and Klf4 overexpression by Hes1 downreg-
ulation as it occurs when Notch signalling is inhibited
[8, 63]. This indicates that besides the effect on angiogen-
esis, Dll4/Notch signaling seems to have an additional role
maintaining the tumor stem cells undifferentiated.
Additionally, Dll4/Notch ubiquitous inhibition pro-
moted the transcription of the cell cycle regulators
cyclin-dependent kinase (CDK) inhibitors Cdkn1b and
Cdkn1c in the ApcMin/+ tumors. A previous report
showed that inactivation of Notch1 and 2 in the normal
gut is associated with derepression of these CDK inhib-
itors [7]. This phenotype was completely abrogated in
the absence of Atoh1 [7, 64], a molecule that is also
considered to act as a tumor suppressor in CRC [65].
Therefore, Dll4/Notch inhibition may also negatively
affect the tumor stem cell populations through Atoh1
derepression-mediated upregulation of the CDK inhibi-
tors Cdkn1b and Cdkn1c.
Conclusions
In summary, we show that Dll4 seems to be the ligand
responsible, at least partially, for the previously reported
Notch effects during intestinal tumor development.
Dll4/Notch deletion seems to inhibit the initiation and
development of intestinal tumorigenesis through angio-
genic and non-angiogenic related mechanisms independ-
ently of β-catenin activation and without affecting the
normal gut. The non-angiogenic associated effects medi-
ated by this pathway blockade may include the inhibition
of tumor cell proliferation, the neoplastic transform-
ation, the maintenance of the tumor stem cells and the
promotion of epithelial differentiation predominantly
towards the secretory cell lineages.
Thus, despite the need for further studies, Dll4/Notch
blockade appears to be a good candidate strategy to pre-
vent CRC in patients predisposed to this disease and
should also be considered in the treatment of early
stages of CRC.
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